|Bid||3,277.00 x 0|
|Ask||3,282.00 x 0|
|Day's Range||3,200.00 - 3,282.00|
|52 Week Range||2,841.50 - 3,545.00|
|Beta (3Y Monthly)||0.89|
|PE Ratio (TTM)||29.49|
|Earnings Date||Oct 28, 2019 - Nov 1, 2019|
|Forward Dividend & Yield||28.00 (0.88%)|
|1y Target Est||6,868.60|
Terumo BCT, a global leader in blood component, therapeutic apheresis and cell therapy technologies, is providing a 3-year grant to Abrale (Associação Brasileira de Linfoma e Leucemia or the Brazilian Association of Lymphoma and Leukemia), a nongovernmental organization working to democratize treatment and improve the quality of life for patients with blood cancer in Brazil. The grant will support clinical research, collection of health outcomes data and clinical guideline creation, including best practices of treatment for leukemia patients. Abrale plans to collect data and use it to advocate for government support of treatments not consistently available to all patients.
Orchestra BioMed, Inc. (Orchestra BioMed), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced it has formed a global strategic partnership with Terumo Corporation (Terumo, TSE: 4543), one of the world’s leading medical device manufacturers, for development and commercialization of Virtue® Sirolimus-Eluting Balloon (SEB), one of its lead assets, in the percutaneous coronary and peripheral interventions field. Virtue SEB is the first and only non-coated drug-eluting angioplasty balloon that delivers a proprietary bioabsorbable, sustained-release formulation of sirolimus, the gold standard drug for preventing restenosis following a percutaneous interventional procedure.
TOKYO, June 13, 2019 /PRNewswire/ -- Terumo Corporation (4543.T), a leading global medical device manufacturer, today announced that it has secured exclusive global development and commercialization rights to Virtue® Sirolimus-Eluting Balloon (SEB) for percutaneous coronary interventions by entering into a strategic partnership with Orchestra BioMed, Inc., a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine. Under the terms of the agreement, Terumo will make a one-time, up-front payment of USD 30 million and an equity commitment of USD 5 million to Orchestra BioMed. Terumo will also make substantial future clinical and regulatory milestone payments to Orchestra BioMed.
ALISO VIEJO, Calif., April 18, 2019 /PRNewswire/ -- MicroVention, Inc., a U.S.-based subsidiary of Terumo Corporation and a global neurovascular company, announced today the publication of the WEB-IT pivotal trial results in the online edition of the Journal of NeuroInterventional Surgery. The WEB® Aneurysm Embolization System met its primary safety and effectiveness endpoints in this prospective, single-arm study of 150 patients conducted at 21 U.S. and 6 international centers.
Antoinette Gawin is expanding Terumo BCT, a biomedical company, beyond its heritage in working with blood centers and hospitals to serve rapidly growing areas of healthcare, such as cell therapy technologies and regenerative medicine. Terumo BCT produces technologies that collect and process blood and cells used in a wide range of therapeutic areas.
ANN ARBOR, Mich., Jan. 23, 2019 /PRNewswire/ -- Terumo Cardiovascular Group, a global leader in cardiovascular surgery technologies, and Talis Clinical, a leading provider of healthcare software solutions, today announced a global strategic partnership. Terumo has made a minority interest investment in the Ohio software company and will provide a distribution channel for Talis Clinical's software into cardiovascular operating rooms (CVOR) and intensive care units (CVICU). The partnership allows Talis Clinical to further expand its products into the cardiac care space.
ALISO VIEJO, Calif., Jan. 7, 2019 /PRNewswire/ -- MicroVention, Inc., a U.S.-based subsidiary of Terumo and a global neurovascular company, announced today the FDA Premarket Approval (PMA) for the WEB Aneurysm Embolization System for the treatment of intracranial wide neck bifurcation aneurysms. The WEB System is the first and only PMA approved device in the new category of intrasaccular flow disruptors for aneurysm embolization.
Monitoring oxygen delivery helps reduce the incidence of Acute Kidney Injury during cardiac surgery ANN ARBOR, Mich. , Nov. 14, 2018 /PRNewswire/ -- Terumo Cardiovascular Group, a global leader in cardiovascular ...